Denintuzumab Mafodotin

Known as: DENITUZUMAB MAFODOTIN, Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody 
An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2018
01219862018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR-directed… (More)
Is this relevant?
2017
2017
Carcinoembryonic antigen (CEA) is a classic tumor-specific antigen that is overexpressed in several cancers, including gastric… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Background We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly… (More)
Is this relevant?
2017
2017
Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2016
2016
A quaternary ammonium-based drug-linker has been developed to expand the scope of antibody-drug conjugate (ADC) payloads to… (More)
  • figure 2
  • figure 3
  • table 1
  • table 2
  • figure 4
Is this relevant?
Review
2016
Review
2016
Monoclonal antibodies represent a major advance in treatment of acute lymphoblastic leukemia (ALL). Targeted delivery of these… (More)
Is this relevant?
2015
2015
The efficacy of an antibody-drug conjugate (ADC) is dependent on the properties of its linker-payload which must remain stable… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Naturally occurring antimitotic pentapeptide dolastatin 10 (1, Figure 1) and its synthetic analogue auristatin E (AE, 2) possess… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Dolastatin 10, a marine natural product peptide, is now known to act as a vascular disrupting agent (VDA). These VDA properties… (More)
Is this relevant?
2004
2004
Current treatments for advanced stage, hormone-resistant prostate cancer are largely ineffective, leading to high patient… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?